Aduro Biotech announces close of IPO
Aduro Biotech announced the closing of its initial public offering of 8,050,000 shares of common stock at a price to the public of $17.00 per share. Net proceeds were $124.3 million. BofA Merrill Lynch and Leerink Partners acted as joint book-running managers for the offering. April 20, 2015